Sunday, May 5, 2013

*THE FDA AND MORE SPECIFICALLY ODAC SAYS NO TO TIVOZANIB IN METASTATIC RENAL CELL CANCER.   TIVOZANIB, a second generation anti-VEGF kinase was being tested against Nexavar.  The panel was not convinced enough to let it win approval.  17 studies were globally reviewed to arrive to this conclusion which will not let the drug moving forward!

*from Medscape
"New guidelines on prostate cancer screening, issued today by the American Urological Association (AUA), are supportive of routine use of the prostate-specific antigen (PSA) test in healthy men, but only for a specified age group, and only after discussion between a man and his physician.
Specifically, the new guidelines state that men 55 to 69 years of age who are at average risk and asymptomatic can consider PSA screening. They should speak to the their physician about the benefits and harms of testing to determine the best course of action." go to full article.
Post a Comment